Warren Center For Neuroscience Drug Discovery
-
Vanderbilt extends its longest ongoing drug discovery agreement with pharmaceutical company through 2023
Vanderbilt has extended its longest ongoing drug discovery agreement with Osaka, Japan-based Ono Pharmaceutical Co., Ltd., a research and development-oriented pharmaceutical company that is committed to creating innovative medicines in specific areas, through November 2023. The initial agreement was signed in November… Read MoreDec. 22, 2021
-
Deciphering the Circuits in Neuroscience Research
Around 500 million people around the world are affected by poor mental health including disorders such as depression, schizophrenia, bipolar disease and dementia with a significant impact on quality of life as well as associated social and economic consequences.1 Boehringer Ingelheim is dedicated to redefining the management of mental health. Read MoreDec. 7, 2021
-
Jeffrey Conn, founding director of Warren Center for Neuroscience Drug Discovery, named 2021 fellow of American Society for Pharmacology and Experimental Therapeutics
Jeffrey Conn, Lee E. Limbird Chair and professor of pharmacology, is among 16 scientists named 2021 fellows of the American Society for Pharmacology and Experimental Therapeutics. Selection as a fellow of ASPET is an honor bestowed on members who have demonstrated excellence… Read MoreSep. 27, 2021